Table 4 Subgroup analyses of the association between main clinic outcomes and monotherapy stratified by outcome predictors
| Â | Adjusted OR (95% CI) | p value | Adjusted OR (95% CI) | p value |
|---|---|---|---|---|
| Â | Male(n=180) | Â | Female(n=99) | Â |
Clinical success | 0.441(0.215-0.904) | 0.025 | 0.840(0.327-2.161) | 0.717 |
Complete clinical success | 1.219(0.615-2.415) | 0.571 | 0.599(0.233-1.540) | 0.287 |
28-day mortality | 1.000(0.422-2.371) | 1.000 | 0.557(0.30-2.383) | 0.430 |
|  | SOFA < 2(n=96) |  | SOFA ≥ 2(n=183) |  |
Clinical success | 0.599(0.190-1.893) | 0.383 | 0.469(0.231-0.953) | 0.036 |
Complete clinical success | 1.065(0.429-2.642) | 0.891 | 0.697(0.332-1.463) | 0.340 |
28-day mortality | 0.777(0.191-3.163) | 0.724 | 0.906(0.376-2.185) | 0.826 |
|  | Charlson Comorbidity Score < 6(n=118) |  | Charlson Comorbidity Score ≥ 6(n=161) |  |
Clinical success | 0.626(0.250-1.565) | 0.316 | 0.467(0.222-0.980) | 0.044 |
Complete clinical success | 0.715(0.309-1.656) | 0.434 | 1.037(0.502-2.142) | 0.922 |
28-day mortality | 2.089(0.596-7.322) | 0.250 | 0.546(0.208-1.433) | 0.219 |